IDH2 and astrocytoma (excluding glioblastoma): Importantly, there appears to be little difference in overall survival between IDH-mutant WHO grade II astrocytomas and WHO grade III IDH-mutant anaplastic astrocytomas, in this instance challenging the current histological approach in assigning a malignancy grade to tumours [40].